Targeting Inc-HLX-2-7 shrinks group 3 medulloblastoma tumours
An intravenous treatment to block lnc-HLX-2-7 from binding to the…
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.